A new strategy of delayed long‐term prophylaxis could prevent cytomegalovirus disease in (D+/R−) solid organ transplant recipients
RS Juan, M Yebra, C Lumbreras… - Clinical …, 2009 - Wiley Online Library
Long‐term prophylaxis against cytomegalovirus (CMV) started immediately after
transplantation in (D+/R−) poses a higher risk of late‐onset CMV disease. Delayed CMV …
transplantation in (D+/R−) poses a higher risk of late‐onset CMV disease. Delayed CMV …
Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients
J Kletzmayr, E Kreuzwieser, T Watkins-Riedel… - …, 2000 - journals.lww.com
Background. Although specific therapy is available with ganciclovir, cytomegalovirus (CMV)
disease remains a major problem after renal transplantation especially in CMV seronegative …
disease remains a major problem after renal transplantation especially in CMV seronegative …
Perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients
G Torres-Madriz, HW Boucher - Clinical infectious diseases, 2008 - JSTOR
Cytomegalovirus (CMV) infection is an important complication of solid-organ transplantation.
The availability of potent antiviral therapies has decreased the incidence of CMV disease …
The availability of potent antiviral therapies has decreased the incidence of CMV disease …
Prophylactic therapy with valgancyclovir in high-risk (cytomegalovirus D+/R−) liver transplant recipients: a single-center experience
M Montejo, E Montejo, M Gastaca, A Valdivieso… - Transplantation …, 2009 - Elsevier
A retrospective study was performed in liver transplant patients with high risk to develop
cytomegalovirus infection (CMV D+/R−) who were treated with valgancyclovir for 3 months …
cytomegalovirus infection (CMV D+/R−) who were treated with valgancyclovir for 3 months …
High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy
H Harvala, C Stewart, K Muller, S Burns… - Journal of medical …, 2013 - Wiley Online Library
Cytomegalovirus infection (CMV) in solid organ transplant recipients is a major clinical
problem. The aim of this study was to evaluate the incidence of CMV infection and its …
problem. The aim of this study was to evaluate the incidence of CMV infection and its …
Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset …
N Singh, C Wannstedt, L Keyes, T Gayowski… - …, 2005 - journals.lww.com
Background. The efficacy of valganciclovir used as preemptive therapy for cytomegalovirus
(CMV) disease in liver transplant recipients is not known. Methods. Between 1996 and 2004 …
(CMV) disease in liver transplant recipients is not known. Methods. Between 1996 and 2004 …
Incidence and severity of cytomegalovirus infection in seropositive heart transplant recipients
BJ Gardiner, JP Bailey, MA Percival… - Clinical …, 2023 - Wiley Online Library
Background The frequency and significance of cytomegalovirus (CMV) infection in
seropositive (R+) heart transplant recipients (HTR) is unclear, with preventative …
seropositive (R+) heart transplant recipients (HTR) is unclear, with preventative …
Increased risk of breakthrough infection among cytomegalovirus donor‐positive/recipient‐negative kidney transplant recipients receiving lower‐dose valganciclovir …
DR Stevens, D Sawinski, E Blumberg… - Transplant Infectious …, 2015 - Wiley Online Library
Objective We compared the effectiveness of lower‐dose (LD)(450 mg/day for 6 months) to
standard‐dose (SD)(900 mg/day for 6 months) valganciclovir (VGCV) prophylaxis for …
standard‐dose (SD)(900 mg/day for 6 months) valganciclovir (VGCV) prophylaxis for …
[HTML][HTML] Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R-transplant recipients
N Perrottet, O Manuel, F Lamoth, JP Venetz… - BMC infectious …, 2010 - Springer
Background Valganciclovir, the oral prodrug of ganciclovir, has been demonstrated
equivalent to iv ganciclovir for CMV disease treatment in solid organ transplant recipients …
equivalent to iv ganciclovir for CMV disease treatment in solid organ transplant recipients …
Patterns of cytomegalovirus infection in simultaneous kidney–pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with …
A Lo, RJ Stratta, MF Egidi… - Transplant infectious …, 2001 - Wiley Online Library
Background: The impact of tacrolimus (TAC), mycophenolate mofetil (MMF) and steroid
immunosuppression on cytomegalovirus (CMV) infection in combination with ganciclovir …
immunosuppression on cytomegalovirus (CMV) infection in combination with ganciclovir …